Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic research and development.
Health Technology Insights: John Morris Joins Guidehouse to Lead Global Health Segment
Despite significant breakthroughs in the understanding, prevention, and treatment of cancer, the disease remains a major challenge, impacting millions of lives and straining healthcare systems. Boehringer Ingelheim is committed to changing this by advancing the discovery and development of new breakthrough treatments for people living with hard-to-treat cancers. With this new collaboration, Boehringer will have access to Tempus’ de-identified database containing molecular, clinical, and imaging data and its analytical platform, Lens. The aim is to explore data derived from patient cohorts to guide biomarker development and patient stratification, develop drug combination hypotheses, support novel target discovery efforts, and educate on patients’ healthcare journey.
“By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our drug discovery and development efforts,” said Mark Paul Petronczki, Head of Oncology Research at Boehringer Ingelheim.
Health Technology Insights: Aranscia Acquires Spesana
“Leveraging real-world patient data is crucial for strengthening our data foundation and harnessing advanced AI methodologies, ultimately accelerating drug development. Integrating these comprehensive datasets with our internal data and techniques not only drives innovation but also enhances the precision and efficiency of pharmaceutical research, paving the way for groundbreaking medical advancements. I am very excited to continue our collaboration with Tempus,” stated Jan Nygaard Jensen, Head of Computational Innovation at Boehringer Ingelheim.
“We look forward to expanding our work with the Boehringer team and the opportunity to deploy multiple of our solutions to their growing oncology pipeline,” said Ryan Fukushima, Chief Operating Officer at Tempus. “We both are firmly committed to applying the power of data and AI to this important research to bring novel treatments to patients faster.”
Health Technology Insights: Marana Health Chooses athenahealth to Enhance Patient and Clinician Experience
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
